Condition
Proteinuric Kidney Disease
Total Trials
5
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (3)
P 4 (1)
Trial Status
Recruiting3
Active Not Recruiting1
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT05312879Phase 2RecruitingPrimary
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
NCT07224776Phase 1Recruiting
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
NCT06830629Phase 2RecruitingPrimary
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06794996Phase 2Active Not RecruitingPrimary
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
NCT01129557Phase 4TerminatedPrimary
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Showing all 5 trials